Notice of Intent to Publish a Funding Opportunity Announcement for Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C - Clinical Trial Not Allowed)
ID: 358935Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358935
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Institutional Network Award aimed at promoting research training in kidney, urologic, and hematologic fields. This initiative seeks to support institutions in developing a robust network to engage and train the next generation of researchers through innovative outreach and career development activities, with each institution eligible to apply for a single award to support at least five trainee slots. The total estimated funding for this program is $4 million, with an award ceiling of $2.1 million, and the NIH anticipates making approximately eight awards. Interested applicants can reach out to Dr. Tracy Rankin at rankint@niddk.nih.gov or (301) 594-4748 for further information, with the estimated synopsis post date set for July 5, 2025, and applications expected to be solicited by October 5, 2025.

    Point(s) of Contact
    Tracy Rankin, Ph.D. National Institute of Diabetes and Digestive and Kidney Diseases
    (301) 594-4748
    rankint@niddk.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive Learning communitY - Coordinating Center (KUH-FAMILY)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive Learning communitY - Coordinating Center (KUH-FAMILY)." This initiative aims to establish a Coordinating Center that will unify and enhance various training and career development programs focused on recruiting, training, and retaining a national community of researchers in kidney, urologic, and hematologic diseases. The program is critical for fostering collaboration and innovation within these health fields, ultimately contributing to improved research outcomes. The estimated total funding for this cooperative agreement is $2,000,000, with one award expected to be made. Interested applicants can reach out to Christine Maric-Bilkan via email at christine.maric-bilkan@nih.gov for further information, with key deadlines including a synopsis close date of July 1, 2026, and an estimated project start date of February 1, 2027.
    Notice of Intent to Publish a Funding Opportunity Announcement for Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the continuation of the NIDDK Hematology Central Coordinating Center (HCC) under a cooperative agreement. The HCC will collaborate with up to five Cooperative Centers of Excellence in Hematology (CCEH) to provide administrative support, develop communication strategies, and implement educational programs aimed at enhancing research in nonmalignant hematology. This initiative is crucial for fostering a national multidisciplinary research effort to study hematopoiesis and address nonmalignant hematologic diseases. The estimated total program funding is $1 million, with a single award anticipated, and the NOFO is expected to be published in December 2024, with applications due by March 2025. For further details, potential applicants should prepare to submit their proposals in alignment with the requirements outlined in the forthcoming NOFO.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network (NCTN) - Network Group Operations Centers, which will require a U10 clinical trial. This initiative aims to provide scientific leadership for the development and implementation of multi-disciplinary, multi-institutional clinical trials targeting various cancer types and populations, focusing on late-phase treatment trials and advanced imaging studies. The funding, estimated at $99.3 million, is intended to support the conduct of essential clinical research for adults, adolescents, and children with cancer, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, applicants should prepare their submissions in advance of the anticipated award date of March 1, 2026.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    Forecast to Publish a Notice of Funding Opportunity for The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (LAOs), with an estimated total program funding of $12 million. This initiative aims to solicit applications from private institutions of higher education to establish or maintain LAOs that will design, conduct, and analyze early phase clinical trials involving investigational agents under the regulatory sponsorship of the NIH's Division of Cancer Treatment and Diagnosis. The ETCTN LAOs will play a critical role in overseeing scientific, programmatic, financial, and administrative aspects of the trials, while also providing mentorship to early-career investigators. The NOFO is expected to be published in Summer 2025, with applications due in Fall 2025. For further inquiries, interested parties can contact Lori A. Henderson, Ph.D., at NCIETCTNRFA@mail.nih.gov or by phone at 240-276-5930.
    Forecast to Publish a Notice of Funding Opportunity for The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Metastasis Research Network (MetNet), specifically targeting research projects under the U01 Clinical Trial Not Allowed funding mechanism. This initiative aims to solicit applications that utilize integrative systems-level approaches to address critical questions in metastasis research, aligning with the ongoing efforts of the MetNet, which focuses on understanding the complex dynamics of metastasis through collaborative research. The anticipated NOFO is expected to be published in Summer 2025, with applications due in Fall 2025, and will support approximately 10 awards, with no cost-sharing or matching requirements. For further inquiries, interested applicants can contact Joanna M. Watson, Ph.D., at watsonjo@mail.nih.gov or by phone at 240-276-6206.
    Notice of Intent to Publish a Funding Opportunity Announcement for Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for a cooperative agreement aimed at advancing research on Type 1 Diabetic nephropathy (T1D). This initiative seeks applications from Recruitment Sites (RS) to enroll adult and pediatric patients with T1D, particularly those at high risk for diabetic nephropathy, into a longitudinal cohort study, which will include protocol-based kidney biopsies. The research will leverage existing resources from the Kidney Precision Medicine Project (KPMP) to create a Kidney Tissue Atlas, identify disease subgroups, and explore novel therapeutic targets. The estimated total program funding for this opportunity is $1.3 million, with the NOFO expected to be published in fall 2024 and applications due in late fall 2024. Interested applicants are encouraged to reach out to the NIDDK contacts provided in the announcement for further information.
    Notice of Intent to Publish a Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Intent for a limited competition grant opportunity titled the Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant under the Clinical and Translational Science Awards (CTSA) Program. This grant aims to enhance postdoctoral research training for individuals holding various doctoral degrees, ensuring a diverse pool of clinical and translational scientists who can advance health-related diagnostics, therapeutics, and interventions. The anticipated Notice of Funding Opportunity (NOFO) is expected to be published in Summer 2024, with applications due by January 2025, and awards projected to be made by December 2025. Interested institutions should prepare to develop collaborative projects in response to this opportunity.
    Forecast to Publish a Notice of Funding Opportunity for The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratory (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the establishment of a Pharmacokinetics Resource Laboratory (PK Laboratory) to support the Experimental Therapeutics Clinical Trials Network (ETCTN). This initiative aims to solicit applications from private institutions of higher education to maintain or establish a laboratory that will facilitate biospecimen collections and analyze pharmacokinetic endpoints, drug-drug interactions, and other critical factors in clinical trials involving NCI Investigational New Drug (IND) agents. The PK Laboratory is essential for advancing the clinical development of these agents and will require a multidisciplinary approach, including technical services, scientific leadership, and biospecimen management. The estimated total program funding is $850,000, with one award anticipated, and the NOFO is expected to be published in Summer 2025, with applications due in Fall 2025. For further inquiries, interested parties can contact Dr. Lori A. Henderson at NCIETCTNRFA@mail.nih.gov or by phone at 240-276-5930.